Pharmacodynamics of glucocorticoids

Clinical and Experimental Rheumatology

Volumn 29, Issue 5 SUPPL. 68, 2011, Pages

  Strehl, C ^a   Spies, C M ^a   Buttgereit, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Effects; Endogenous glucocorticoids; Genomic effects; Glucocorticoid; Glucocorticoid receptor; Mechanisms; Non genomic effects; Pharmacodynamics

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PREDNISONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DERMATOMYOSITIS; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; GENOMICS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; METABOLIC DISORDER; MYOSITIS; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

GENOMICS; GLUCOCORTICOIDS; HUMANS; IMMUNE SYSTEM; RHEUMATIC DISEASES;

EID: 81155148766     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. BUTTOEREIT F, SAAG KG, CUTOLO M, DA SILVA JA, BIJLSMA JW: The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005; 34: 14-21. (Pubitemid 40445053)
2. STAHN C, BUTTGEREIT F: Genomic and non-genomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4: 525-33.
3. SCHACKE H, SCHOTTELIUS A, DOCKE WD et al.: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101: 227-32. (Pubitemid 38084232)
4. NUSSEY S, WHITEHEAD S: Endocrinology. 1st ed., Oxford, BIOS Scientific Publishers, 2001: Chapter 4, Adrenal Gland.
5. HENCH PS: Potential Reversibility of Rheumatoid Arthritis. Ann Rheum Dis 1949; 8: 90-6.
6. HENCH PS, KENDALL EC et al.: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 1949; 24: 181-97.
7. HENCH PS, SLOCUMB CH et al.: The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report. Mayo Clin Proc 1949; 24: 277-97.
8. SCHACKE H, DOCKE WD, ASADULLAH K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43. (Pubitemid 35346616)
9. BUTTGEREIT F, BURMESTER GR, LIPWORTH BJ: Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005; 365:801-3. (Pubitemid 40311369)
10. BUTTGEREIT F, SEIBEL J, BIJLSMA JW: Glucocorticoids. In: RICH RR, FLEISHER TA, SHEARER WT, SCHROEDER HW, FREW AJ, WEYAND CM (Eds.): Clinical Immunology: Principles and Practice. 3rd ed., Philadelphia, Mosby, 2008: Chapter 87, p. 1293-306.
11. STAHN C, LOWENBERG M, HOMMES DW, BUTTGEREIT F: Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275:71-8. (Pubitemid 47259281)
12. VACCA A, FELLI MP, FARINA AR et al.: Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992; 175: 637-46.
13. DE BOSSCHER K, VANDEN BERGHE W, VERMEULEN L, PLAISANCE S, BOONE E, HAEGEMAN G: Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000; 97: 3919-24. (Pubitemid 30226062)
14. BEATO M: Gene regulation by steroid hormones. Cell 1989; 56: 335-44. (Pubitemid 19052651)
15. KIRWAN JR, BIJLSMA JW, BOERS M, SHEA BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007: CD006356.
16. SPIES CM, BIJLSMA JW, BURMESTER GR, BUTTGEREIT F: Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010; 10:302-7.
17. DA SILVA JA, JACOBS JW, KIRWAN JR et al.: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-93. (Pubitemid 43268214)
18. BUTTGEREIT F, BURMESTER, GR: Glucocorticoids. In: KLIPPEL JH, STONE JH, CROFFORD LJ, WHITE PH (Eds.): Primer on the Rheumatic Diseases. 13th ed., New York, Springer, 2008: Chapter 42, pp. 644-50.
19. BIJLSMA JW, BUTTGEREIT F, JACOBS WG: Systemic and intra-articular glucocorticoids in rheumatoid arthritis. In: FIRESTEIN GS, PANAYI GS, WOLLHEIM F (Eds.): Rheumatoid Arthritis. 2nd ed., USA, Oxford University Press, 2006: Chapter 23.
20. BUTTGEREIT F, dA SILVA JA, BOERS M et al.: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22. (Pubitemid 34787710)
21. BUTTGEREIT F, STRAUB RH, WEHLING M, BURMESTER GR: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50:3408-17. (Pubitemid 39488664)
22. JACOBS JWG, BIJLSMA JWJ: Glucocorticoid therapy. In: FIRESTEIN GS, BUDD RS, HARRIS ED, MCINNES IB, RUDDY S, SERGENT JS (Eds.): Kelley's Textbook of Rheumatology. 8th ed., Philadelphia, Saunders Elsevier, 2008: Chapter 55, pp. 863-81.
23. KAISER HK: Cortisontherapie - Corticoide in Klinik und Praxis. 11th ed., Stuttgart, New York, Georg Thieme Verlag, 2002, pp. 87-91.
24. BUTTGEREIT F, BURMESTER GR, STRAUB RH, SEIBEL MJ, ZHOU H: Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011; 63: 1-9.
25. DRAPER N, STEWART PM: 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005; 186: 251-71. (Pubitemid 41167396)
26. COOPER MS, BUJALSKA I, RABBITT E et al.: Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001; 16: 1037-44. (Pubitemid 32467147)
27. HARDY R, RABBITT EH, FILER A et al.: Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008; 67: 1204-10.
28. ADCOCK IM, LANE SJ: Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003; 178: 347-55. (Pubitemid 37220162)
29. WIKSTROM AC: Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness. J Endocrinol 2003; 178: 331-7.
30. ALMAWI WY, MELEMEDJIAN OK: Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002; 71: 9-15. (Pubitemid 34062768)
31. BUTTGEREIT F, SCHEFFOLD A: Rapid glucocorticoid effects on immune cells. Steroids 2002; 67: 529-34. (Pubitemid 34311770)
32. PRATT WB: The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998; 217: 420-34.
33. LOWENBERG M, STAHN C, HOMMES DW, BUTTGEREIT F: Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2007.
34. HOLLENBERG SM, WEINBERGER C, ONG ES et al.: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-41. (Pubitemid 16172412)
35. LU NZ, CIDLOWSKI JA: The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci 2004; 1024: 102-23. (Pubitemid 38879596)
36. BODWELL JE, ORTI E, COULL JM, PAPPIN DJ, SMITH LI, SWIFT F: Identification of phosphorylated sites in the mouse glucocorticoid receptor. J Biol Chem 1991; 266: 7549-55. (Pubitemid 21906400)
37. WEBSTER JC, JEWELL CM, BODWELL JE, MUNCK A, SAR M, CIDLOWSKI JA: Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 1997; 272: 9287-93. (Pubitemid 27154940)
38. CHEN R, BURKE TF, CUMBERLAND JE et al.: Glucocorticoids inhibit calcium- and calcineurin-dependent activation of the human IL-4 promoter. J Immunol 2000; 164: 825-32. (Pubitemid 30043706)
39. HECK S, BENDER K, KULLMANN M, GOTTLICHER M, HERRLICH P, CATO AC: I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. Embo J 1997; 16:4698-707. (Pubitemid 27326607)
40. MORI A, KAMINUMA O, SUKO M et al.: Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 1997; 89: 2891-900. (Pubitemid 27172576)
41. CATO AC, NESTL A, MINK S: Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002; 2002: RE9.
42. CROXTALL JD, CHOUDHURY Q, FLOWER RJ: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000; 130: 289-98. (Pubitemid 30261038)
43. FALKENSTEIN E, NORMAN AW, WEHLING M: Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 2000; 85: 2072-5. (Pubitemid 32269322)
44. HAFEZI-MOGHADAM A, SIMONCINI T, YANG Z et al.: Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8: 473-9. (Pubitemid 34546749)
45. BUTTGEREIT F, BURMESTER GR, BRAND MD: Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000; 21: 192-9. (Pubitemid 30184792)
46. PRATT WB, MORISHIMA Y, MURPHY M, HARRELL M: Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 2006: 111-38.
47. GAMETCHU B, CHEN F, SACKEY F, POWELL C, WATSON CS: Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Steroids 1999; 64: 107-19. (Pubitemid 29168594)
48. ORCHINIK M, MURRAY TF, MOORE FL: A corticosteroid receptor in neuronal membranes. Science 1991; 252: 1848-51. (Pubitemid 21917109)
49. BARTHOLOME B, SPIES CM, GABER T et al.: Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. Faseb J 2004; 18: 70-80. (Pubitemid 38076467)
50. SONG IH, BUTTGEREIT F: Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 2006; 246: 142-6. (Pubitemid 43238408)
51. TRYC AB, SPIES CM, SCHNEIDER U et al.: Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 2006; 33: 2249-53. (Pubitemid 44749785)
52. GAMETCHU B, WATSON CS, WU S: Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. Faseb J 1993; 7: 1283-92. (Pubitemid 23314365)
53. SPIES CM, SCHAUMANN DH, BERKI T et al.: Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway. Ann Rheum Dis 2006; 65: 1139-46. (Pubitemid 44277386)
54. SCHMIDT J, METSELAAR JM, WAUBEN MH, TOYKA KV, STORM G, GOLD R: Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003; 126: 1895-904. (Pubitemid 36917348)
55. METSELAAR JM, WAUBEN MH, WAGENAARHILBERS JP, BOERMAN OC, STORM G: Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003; 48: 2059-66. (Pubitemid 36828702)
56. PAUL-CLARK MJ, MANCINI L, DEL SOLDATO P, FLOWER RJ, PERRETTI M: Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci USA 2002; 99: 1677-82. (Pubitemid 34136552)
57. PAUL-CLARK MJ, ROVIEZZO F, FLOWER RJ et al.: Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol 2003; 171: 3245-52. (Pubitemid 37093551)
58. PERRETTI M, PAUL-CLARK MJ, MANCINI L, FLOWER RJ: Generation of innovative antiinflammatory and anti-arthritic glucocorticoid derivatives that release NO: the nitrosteroids. Dig Uver Dis 2003; 35 (Suppl. 2): S41-8. (Pubitemid 41070469)
59. LIN CW, NAKANE M, STASHKO M et al.: Trans-activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y 1)-1 H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers. Mol Pharmacol 2002; 62: 297-303. (Pubitemid 34804109)
60. BELVISI MG, WICKS SL, BATTRAM CH et al.: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001; 166: 1975-82. (Pubitemid 32114685)
61. VAYSSIERE BM, DUPONT S, CHOQUART A et al.: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997; 11: 1245-55. (Pubitemid 28041332)
62. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14.
63. STRAUB RH, DHABHAR FS, BIJLSMA JW, CUTOLO M: How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum 2005; 52: 16-26. (Pubitemid 40129228)
64. BUTTGEREIT F, ZHOU H, SEIBEL MJ: Arthritis and endogenous glucocorticoids: the emerging role of the 11beta-HSD enzymes. Ann Rheum Dis 2008; 67: 1201-3.
65. GATHERCOLE LL, STEWART PM: Targeting the pre-receptor metabolism of Cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 2010; 122: 21-7.
66. COOPER DA, DUCKETT M, HANSEN P, PETTS V, PENNY R: Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. Clin Exp Immunol 1981; 44: 129-36. (Pubitemid 11139680)
67. BROUG-HOLUB E, KRAAL G: Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin Exp Immunol 1996; 104: 332-6. (Pubitemid 26139780)
68. BARBER AE, COYLE SM, MARANO MA et al.: Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999-2006. (Pubitemid 23129678)
69. CALANDRA T, BERNHAGEN J, METZ CN et al.: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377:68-71.
70. FRANCHIMONT D: Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. AnnN Y Acad Sci 2004; 1024: 124-37. (Pubitemid 38879597)
71. GEBAUER F, OTTENDORFER D, KUNZE R, MAASCH HJ: Influence of a co-stimulation of human leucocytes with an Escherichia coli preparation and fixed immunoglobulins on cytokine release in the presence of hydrocortisone. Arzneimittelforschung 2001; 51: 180-7. (Pubitemid 32176252)
72. LIM HY, MULLER N, HEROLD MJ, VAN DEN BRANDT J, REICHARDT HM: Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007; 122:47-53. (Pubitemid 47222594)
73. NOCENTINI G, RICCARDI C: GITR: a modulator of immune response and inflammation. Adv Exp Med Biol 2009; 647: 156-73.
74. RENZ H, HENKE A, HOFMANN P et al.: Sensitization of rat alveolar macrophages to enhanced TNF-alpha release by in vivo treatment with dexamethasone. Cell Immunol 1992; 144: 249-57.
75. WIEGERS GJ, LABEUR MS, STEC IE, KLINKERT WE, HOLSBOER F, REUL JM: Glucocorticoids accelerate anti-T cell receptor-induced T cell growth. J Immunol 1995; 155: 1893-902.
76. WIEGERS GJ, STEC IE, KLINKERT WE, REUL JM: Glucocorticoids regulate TCR-induced elevation of CD4: functional implications. J Immunol 2000; 164: 6213-20. (Pubitemid 30408800)
77. DHABHAR FS, MILLER AH, MCEWEN BS, SPENCER RL: Effects of stress on immune cell distribution. Dynamics and hormonal mechanisms. J Immunol 1995; 154: 5511-27.
78. DHABHAR FS, MCEWEN BS: Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999; 96: 1059-64. (Pubitemid 29072183)
79. COX G: Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995;154:4719-25.
80. LILES WC, DALE DC, KLEBANOFF SJ: Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995; 86: 3181-8.
81. STRAUSBAUGH HJ, ROSEN SD: A potential role for annexin 1 as a physiologic mediator of glucocorticoid-induced L-selectin shedding from myeloid cells. J Immunol 2001; 166: 6294-300. (Pubitemid 32440762)
82. PIEMONTI L, MONTI P, ALLAVENA P, LEONE BE, CAPUTO A, DI CARLO V: Glucocorticoids increase the endocytic activity of human dendritic cells. Int Immunol 1999; 11: 1519-26. (Pubitemid 29425743)